Literature DB >> 9371374

Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles.

O Hantz1, C Borel, C Trabaud, F Zoulim, J Dessolin, M Camplo, P Vlieghe, M Bouygues, C Trepo, J L Kraus.   

Abstract

The antiviral activity of a new class of N,N,N',N",NA'''-pentakis (omega-aminoalkyl) tetraazamacrocycles was evaluated in primary duck hepatocyte cultures infected with the duck hepatitis B virus (DHBV). Three of the four tested compounds were able to selectively inhibit DHBV replication by acting at an early step of the hepadnavirus infection but were associated with significant toxicity.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9371374      PMCID： PMC164169     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study.

Authors:  M Krüger; H L Tillmann; C Trautwein; U Bode; K Oldhafer; H Maschek; K H Böker; C E Broelsch; R Pichlmayr; M P Manns
Journal:  Liver Transpl Surg       Date:  1996-07

2.  Application of the neutral red assay (NR assay) to monolayer cultures of primary hepatocytes: rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS).

Authors:  R Fautz; B Husein; C Hechenberger
Journal:  Mutat Res       Date:  1991-10       Impact factor: 2.433

Review 3.  The treatment of chronic viral hepatitis.

Authors:  J H Hoofnagle; A M di Bisceglie
Journal:  N Engl J Med       Date:  1997-01-30       Impact factor: 91.245

4.  Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification.

Authors:  J Summers; P M Smith; A L Horwich
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

5.  Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus.

Authors:  D J Petcu; C E Aldrich; L Coates; J M Taylor; W S Mason
Journal:  Virology       Date:  1988-12       Impact factor: 3.616

6.  In vivo neutralization of duck hepatitis B virus by antibodies specific to the N-terminal portion of pre-S protein.

Authors:  V Lambert; S Chassot; A Kay; C Trepo; L Cova
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

7.  Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.

Authors:  S L Doong; C H Tsai; R F Schinazi; D C Liotta; Y C Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

8.  2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.

Authors:  F Zoulim; E Dannaoui; C Borel; O Hantz; T S Lin; S H Liu; C Trépo; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  Therapeutic basis of glycyrrhizin on chronic hepatitis B.

Authors:  H Sato; W Goto; J Yamamura; M Kurokawa; S Kageyama; T Takahara; A Watanabe; K Shiraki
Journal:  Antiviral Res       Date:  1996-05       Impact factor: 5.970

10.  Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement.

Authors:  A R Jilbert; T T Wu; J M England; P M Hall; N Z Carp; A P O'Connell; W S Mason
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103
View more
  4 in total

1.  In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.

Authors:  A-C Jacquard; M-N Brunelle; C Pichoud; D Durantel; S Carrouée-Durantel; C Trepo; F Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

2.  In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.

Authors:  M N Brunelle; J Lucifora; J Neyts; S Villet; A Holy; C Trepo; F Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

3.  Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.

Authors:  F Le Guerhier; C Pichoud; S Guerret; M Chevallier; C Jamard; O Hantz; X Y Li; S H Chen; I King; C Trépo; Y C Cheng; F Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

4.  Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.

Authors:  Béatrice Seignères; Perrine Martin; Bettina Werle; Olivier Schorr; Catherine Jamard; Laurence Rimsky; Christian Trépo; Fabien Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.